Clever combo: multi-modality imaging developed by novel optics

Article

Funding novel optics and imaging software encourages the evolution of multi-modality imaging and provides more business opportunities.

Funding novel optics and imaging software encourages the evolution of multi-modality imaging and provides more business opportunities, according to the latest analysis from Frost and Sullivan.

The publication, "Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging (Technical Insights)", demonstrates that the development of novel optics, data acquisition methods and image processing software has significantly encouraged the evolution of optical imaging technologies.

Optical imaging, at both macroscopic and microscopic levels, are frequently used by clinicians to image tissues with enhanced contrast and resolution capabilities.

Prasanna Vadhana Kannan, Senior Research Analyst at Technical Insights, said, "Technology trends are moving from conventional confocal microscopy to optical coherence tomography (OCT), with the adoption of newer technologies such as adaptive optics and polarization imaging in ophthalmology. Several start-ups are developing innovative technologies, most of which are in the near completion and advanced phases of clinical approval in the optical imaging market."

Kannan continued, "OCT is truly an easy-to-use modality that provides digital cellular 2-D and 3-D imaging solutions for clinical and research pathology lab application needs on fixed or fresh tissue. Further refinement could result in achieving significantly higher resolution capabilities and better differentiation of cancerous lesions, embryology studies, and stem cells (involving therapeutics research)."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.